Aptus will leader the funded project PREDIAPT. This project is supported by Spanish MICINN within program RETOS-COLABORACIÓN 2019 (RTC2019-007229-1)

PREDIAPT will develop two pronostic applications of treatment response with Pt in Lung Cancer patients using MAFG as biomarker by means of (i) an ELONA, using aptamers to measure MAFG levels in blood to monitor the process in liquid biopsias as well as (ii) a pronostic system based on apta-histochemistry using aptamers against MAFG in tumoral samples.